Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

Michael Friedländer, Tarek Meniawy, Ben Markman, +10

The Lancet Oncology

MedicinePharmacologyAdvanced Solid TumoursDose-escalation StagePharmacotherapy +4

Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma

Loryn Holokai, Jayati Chakrabarti, Joanne Lundy, +15

Cancers

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?

Henry Shen, Joanne Lundy, Andrew Strickland, +5

Cells

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedländer, Tarek Meniawy, Ben Markman, +10

Journal of Clinical Oncology

ImmunologyImmunoeditingImmunotherapeuticsImmunotherapyAdvanced Solid Tumors +15

Pulmonary metastases, a potential biologic consequence of anesthetic-induced immunosuppression by thiopental.

Joanne Lundy, Lovett Ej, Philip B. Conran

PubMed

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedländer, Tarek Meniawy, Ben Markman, +11

Journal of Clinical Oncology

ImmunologyImmunoeditingImmunotherapeuticsImmunotherapyAdvanced Solid Tumors +15

Blockade of the protease ADAM17 ameliorates experimental pancreatitis

Mohamed I. Saad, Teresa Weng, Joanne Lundy, +10

Proceedings of the National Academy of Sciences

A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.

Jayesh Desai, Ben Markman, Sumitra Ananda, +15

Journal of Clinical Oncology

ImmunologyPathologyPharmacotherapyOncologyCombined Braf +15

TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma

Joanne Lundy, Linden J. Gearing, Hugh Gao, +9

Oncogene

OncologyChemotherapy ResponsePancreatic CancerMedicineImmunology +8

Targeted Transcriptome and <i>KRAS</i> Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer

Joanne Lundy, Hugh Gao, William L. Berry, +3

Clinical Cancer Research